Looks like you’re on the UK site. Choose another location to see content specific to your location
Amgen to present new cancer compounds at AACR 2018
Amgen has announced that it will be attending this year's American Association for Cancer Research (AACR) annual meeting, where it will share its latest drug development findings.
Preclinical data for several novel investigational oncology candidates will be presented at the conference in Chicago from April 14th to 18th, with findings spanning Amgen's early pipeline, including the first presentations of data for several compounds.
These include the company's most advanced chimeric antigen receptor T-cell therapy programmes, targeting DLL3 in small cell lung cancer and FLT3 in acute myeloid leukaemia, while two studies showcasing the Mcl-1 inhibitor AMG 176 will also be presented.
In addition, Amgen will present preclinical data evaluating its half-life extended anti-BCMA BiTE for the treatment of multiple myeloma for the first time, with a phase I study evaluating the drug currently ongoing.
David Reese, senior vice-president of translational sciences and oncology at Amgen, said: "As part of our overarching research and development strategy, Amgen is committed to advancing multiple modalities to gain biological insights before selecting the optimal treatment approach."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard